Alexander Stein

11PUBLICATIONS
55CO-AUTHORS
ChemotherapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 23, 2026
Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial.

|May 19, 2026
Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group.

|Oct 18, 2025
Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial.

Alexander Stein, Eray Goekkurt, Salah-Eddin Al-Batran

|Nov 11, 2024
Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy.

Joseph Tintelnot, Lisa Paschold, Eray Goekkurt

|Sep 15, 2022
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.

Robert J Kreitman, Philippe Moreau, Farhad Ravandi

|Apr 21, 2022
Immunotherapy in Squamous Cell Cancer of the Esophagus.

Peter Thuss-Patience, Alexander Stein

Pageof 2

Frequent Collaborators

3 joint publications

Joseph Tintelnot

2 joint publications

Viktor Grünwald

2 joint publications

Hans-Joachim Schmoll

2 joint publications

Peter Thuss-Patience